Clinical Trial Search

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 2; 3; 1 Participants

Primary: Cmax of NAC After Single Dose Administration of Test and Reference — 2804.38; 3215.63 ng/mL — p=0.0136

Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted — 2.39; 1.18; 1.52; 0.13 Percent predicted — p=0.325

Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g

Primary: HbA1c — -1.73; -1.73; -1.25 mean change from baseline

Primary: Change in Serum Trimethylamine N-oxide (TMAO) — -3.9; 0.5 uM

Primary: Objective Response Rate (ORR) — 4 percentage of participants

Primary: Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous…

Primary: Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline up to 8 Weeks Treatment — 5 Participants

Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants

Primary: Serum CNP Levels of PCOS and Healthy Participants — 110; 57 pg/ml — p=0.004

Primary: Number of Participants Stratified by Edmonton Symptom Assessment System (Revised Version) (ESAS-r) Pain Scores — 50; 43; 7; 7 Participants

Primary: Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALS — 17; 34; 8; 11 Participants

Primary: Total Anti-pneumococcal IgG Levels at Baseline, Week 0, Week 8 and Week 16 — 109.8; 53.9; 142.3; 53.9 mcg/dL

Primary: Overall Survival (OS) in the Global Population — 13.24; NA; 13.40; 19.22 months — p=0.0006